Veradermics, Incorporated
Veradermics, Incorporated operates as a biopharmaceutical company focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in the de… Read more
Veradermics, Incorporated (MANE) - Total Assets
Latest total assets as of September 2025: $18.80 Million USD
Based on the latest financial reports, Veradermics, Incorporated (MANE) holds total assets worth $18.80 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Veradermics, Incorporated - Total Assets Trend (2023–2024)
This chart illustrates how Veradermics, Incorporated’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Veradermics, Incorporated - Asset Composition Analysis
Current Asset Composition (December 2024)
Veradermics, Incorporated's total assets of $18.80 Million consist of 93.5% current assets and 6.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 89.4% |
| Accounts Receivable | $1.38 Million | 2.3% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2023–2024)
This chart illustrates how Veradermics, Incorporated's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Veradermics, Incorporated's current assets represent 93.5% of total assets in 2024, a decrease from 95.2% in 2023.
- Cash Position: Cash and equivalents constituted 89.4% of total assets in 2024, up from 88.3% in 2023.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2023.
- Asset Diversification: The largest asset category is accounts receivable at 2.3% of total assets.
Veradermics, Incorporated Competitors by Total Assets
Key competitors of Veradermics, Incorporated based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Veradermics, Incorporated - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Veradermics, Incorporated generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Veradermics, Incorporated is currently not profitable relative to its asset base.
Veradermics, Incorporated - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.29 | 11.77 | - |
| Quick Ratio | 3.29 | 11.77 | - |
| Cash Ratio | 0.00 | 0.00 | - |
| Working Capital | $13.02 Million | $ 50.82 Million | - |
Veradermics, Incorporated - Advanced Valuation Insights
This section examines the relationship between Veradermics, Incorporated's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | 221.8% |
| Total Assets | $59.38 Million |
| Market Capitalization | $605.02K USD |
Valuation Analysis
Below Book Valuation: The market values Veradermics, Incorporated's assets below their book value (0.01 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Veradermics, Incorporated's assets grew by 221.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Veradermics, Incorporated (2023–2024)
The table below shows the annual total assets of Veradermics, Incorporated from 2023 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $59.38 Million | +221.75% |
| 2023-12-31 | $18.46 Million | -- |